Value assessment in metastatic colorectal cancer is becoming increasingly complex due to multiple treatment options and competing decision criteria.
This study applies a multicriteria decision analysis (MCDA) framework to capture value beyond traditional endpoints, integrating clinical, economic and patient-reported outcomes. Findings indicate that trifluridine/tipiracil plus bevacizumab delivers a positive overall value contribution compared to available alternatives, with efficacy and safety—particularly overall survival—playing a decisive role in the evaluation.
This approach highlights the need for multidimensional value frameworks to better align treatment positioning with real-world value delivered to healthcare systems.